Literature DB >> 26614028

Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.

Aurélie Mbeutcha1, Ilaria Lucca2, Romain Mathieu3, Yair Lotan4, Shahrokh F Shariat5.   

Abstract

The standard of care for detection and surveillance of bladder cancer consists of cytology and cystoscopy, but both examinations suffer from many limitations, including issues related to accuracy, invasiveness, and cost. Several noninvasive methods for detection and surveillance of bladder cancer have been developed and urine-based biomarkers seem the most promising. This nonsystematic review critically analyzes the commercially available biomarkers and highlights some upcoming investigational biomarkers. To date, none of these biomarkers has sufficient validation to serve as a reliable alternative to cystoscopy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Detection; Follow-up; Surveillance; Transitional cell carcinoma; Urinary biomarkers; Urine; Urothelial carcinoma

Mesh：

Substances：

Year:  2016        PMID： 26614028     DOI： 10.1016/j.ucl.2015.08.005

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  28 in total

1.  Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: Detection of bladder cancer.

Authors:  I Sokolov; M E Dokukin; V Kalaparthi; M Miljkovic; A Wang; J D Seigne; P Grivas; E Demidenko
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

Review 2.  Current Use and Promise of Urinary Markers for Urothelial Cancer.

Authors:  William Tabayoyong; Ashish M Kamat
Journal:  Curr Urol Rep       Date:  2018-10-17       Impact factor: 3.092

Review 3.  Guideline of guidelines: non-muscle-invasive bladder cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia; Yair Lotan
Journal:  BJU Int       Date:  2017-01-24       Impact factor: 5.588

4.  Urinary micro-RNA expressions and protein concentrations may differentiate bladder cancer patients from healthy controls.

Authors:  Gökçe Güllü Amuran; Ilker Tinay; Deniz Filinte; Can Ilgin; Irem Peker Eyüboğlu; Mustafa Akkiprik
Journal:  Int Urol Nephrol       Date:  2019-11-02       Impact factor: 2.370

5.  Simple and Efficient Stratification of Invasive Bladder Cancer Patients.

Authors:  Jerome Zoidakis
Journal:  EBioMedicine       Date:  2016-08-28       Impact factor: 8.143

Review 6.  Circulating Biomarkers in Bladder Cancer.

Authors:  Lakshminarayanan Nandagopal; Guru Sonpavde
Journal:  Bladder Cancer       Date:  2016-10-27

7.  Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma.

Authors:  Shahrokh F Shariat; Romain Mathieu
Journal:  Transl Androl Urol       Date:  2016-10

8.  Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer.

Authors:  Ralf Kittler; Christine Shiang; Ryan Hutchinson; Rahul K Kollipara; Payal Kapur; Francis Franto; Yair Lotan
Journal:  Oncotarget       Date:  2018-01-06

9.  Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation.

Authors:  Despina Chatziharalambous; Vasiliki Lygirou; Agnieszka Latosinska; Konstantinos Stravodimos; Antonia Vlahou; Vera Jankowski; Jerome Zoidakis
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

10.  Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Authors:  Rossana Critelli; Francesca Fasanelli; Marco Oderda; Silvia Polidoro; Manuela Bianca Assumma; Clara Viberti; Mirko Preto; Paolo Gontero; Giuseppina Cucchiarale; Irene Lurkin; Ellen C Zwarthoff; Paolo Vineis; Carlotta Sacerdote; Giuseppe Matullo; Alessio Naccarati
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.